Citations

Clear

5 citation(s) found for "Graham, Richard".

GCT-05. UPDATED REPORT ON TREATMENT MODALITIES IN METASTATIC GERMINOMA IN CHILDREN: A MULTI-INSTITUTIONAL ANALYSIS
Thia, Alexia, Su, Jack M., MacDonald, Shannon M. , Perkins, Stephanie M., Govender, Dinisha , Foo, Jen Chun , Rajagopal, Revathi , O’Halloran, Katrina , Sleightholm, Richard, Lafay‐Cousin, Lucie , Cansanay, Rose Daynielle A, Schlosser, Mary-Pat , Cappellano, Andréa Maria , Dassi, Natália , Fisher, Michael J. , Graham, Richard , Baglivo, Sofía Jares, Ronsley, Rebecca , Khan, Sara , Magnum, Ross, Hoffman, Lindsey M. , Knowles, Truman , Mueller, Sabine , Zaghloul, Mohamed S. , Abdelhaleem, Nada A, El‐Ayadi, Moatasem , Abdelbaki, Mohamed S , Shatara, Margaret , Abu-Arja, Mohammad H , Gorsi, Hamza S. , Dholaria, Hetal , Schwartz, Jonathan, Bartels, Ute , Amayiri, Nisreen Yousef , Yılmaz, Yasin , Czogała, Małgorzata , Mastronuzzi, Angela , Michaiel, George

Mayo Clinic

Neuro-Oncology | June 18, 2024 | Volume: 26 | Issue: Supplement_4 | Pages: 0-0

10.1093/neuonc/noae064.260 Get It

Abstract BACKGROUND Primary intracranial germ cell tumors (GCTs) are rare heterogeneous tumors; germinoma accounts for two-thirds of cases. While neoadjuvant chemotherapy followed by response-based reduced radiotherapy dose and field is the established approach for managing localized CNS germinomas, controversy persists regarding the treatment of primary metastatic disease. Additionally, limited research exists on the utilization of neoadjuvant chemotherapy in primary metastatic germinoma. METHODS A retrospective multi-institutional analysis was conducted to assess overall survival (OS) and event-free survival (EFS) among patients diagnosed with metastatic germinoma who were treated with various modalities. RESULTS We identified 88 patients, including 63 males and 25 females. The median age at presentation was 13.5 years. All patients, who had undergone both brain and spine MRIs, had their diagnoses confirmed through a biopsy, positive CSF cytology, and/or positive CSF tumor markers at presentation. Primary Tumor location was pineal (n=37), suprasellar (n=27), bifocal (n=14) and others (n=9). Eight patients underwent subtotal resection. Craniospinal irradiation (CSI; 21-24 Gy) was administered to 71 patients (81%), while eight patients (9%) received whole ventricular irradiation (WVI; 23.4-30 Gy). Whole brain radiation was given to four patients (5%; 24 Gy), and two patients (2%) had unknown fields. Boosts to primary and/or metastatic sites were administered in all but seven patients. Notably, thirty patients (34%) received CSI without neoadjuvant chemotherapy. At the end of therapy, 69 patients had complete response, 10 partial response and the response was unknown in six. Three patients did not receive irradiation, all died of disease progression. The median follow-up was 64 months (range 6-159 months), yielding an OS of 96.6%. Ongoing multi-institutional data collection and analysis will be presented at the meeting. CONCLUSION Our study is one of the largest studies to date in metastatic germinoma and may provide insight into the role of neoadjuvant chemotherapy with lower CSI doses.
Evaluating Patients With Impaired Renal Function During Drug Development: Highlights From the 2019 US FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting
Sahre, Martina , Milligan, Lauren, Madabushi, Rajanikanth , Graham, Richard, Reynolds, Kellie S., Benjamin, Jessica M., Burckart, Gilbert J. , Schuck, Robert N. , Thompson, Aliza M., Zineh, Issam, Terzic, André , Huang, Shiew‐Mei

Mayo Clinic

Clinical Pharmacology & Therapeutics | January 10, 2021 | Volume: 110 | Issue: 2 | Pages: 285-288

10.1002/cpt.2151 | PMID 33411946 Get It

Patients with multiple chronic conditions, including more advanced chronic kidney disease (CKD), are often excluded from clinical trials, creating challenges in deriving appropriate dosing information and labeling. This article summarizes the May 7, 2019, US Food and Drug Administration Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting, which solicited expert opinions on how to enroll patients with more advanced CKD into clinical trials as well as the assumptions behind and different approaches of exposure‐matching.
Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme
Sandborn, William J. , Nguyen, Deanna D. , Beattie, David T. , Brassil, Patrick, Krey, W. D., Woo, Jacky, Situ, Eva, Sana, Reuben, Sandvik, Erik, Pulido‐Rios, M. Teresa, Bhandari, Raj, Leighton, Jonathan A. , Ganeshappa, Ravi, Boyle, David L. , Abhyankar, Brihad, Kleinschek, Melanie A., Graham, Richard, Krey, Whitney, Panés, Julián

Mayo Clinic

Journal of Crohn's and Colitis | March 6, 2020 | Volume: 14 | Issue: 9 | Pages: 1202-1213

10.1093/ecco-jcc/jjaa049 | PMID 32161949 Get It

Abstract Background and Aims Oral systemic pan-Janus kinase [JAK] inhibition is effective for ulcerative colitis [UC] but is limited by toxicities. We describe preclinical to clinical translation of TD-1473—an oral gut-selective pan-JAK inhibitor—from in vitro characterization through a Phase 1b study in patients with UC. Methods TD-1473 JAK inhibition potency was evaluated in vitro; plasma pharmacokinetics, safety and efficacy were assessed in mice. In a first-time-in-human study, plasma pharmacokinetics and safety were assessed after single and multiple [14 days] ascending doses administered orally to healthy subjects. The Phase 1b study randomized patients with moderately to severely active UC to receive once-daily oral TD-1473 20, 80 or 270 mg, or placebo for 28 days. Plasma and colonic tissue concentrations were measured; safety was assessed; and efficacy was evaluated by UC clinical parameters, disease-surrogate biomarkers, endoscopy, histology and colonic tissue JAK signalling. Results TD-1473 exhibited potent pan-JAK inhibitory activity in vitro. Oral TD-1473 administration to mice achieved high, biologically active colonic tissue concentrations with low plasma exposure and decreased oxazolone-induced colitis activity without reducing blood cell counts vs placebo. TD-1473 administration in healthy human subjects and patients with UC yielded low plasma exposure and was generally well tolerated; treatment in patients with UC resulted in biologically active colonic tissue concentrations and descriptive trends toward reduced clinical, endoscopic and histological disease activity vs placebo. Conclusion Gut-selective pan-JAK inhibition with TD-1473 administration resulted in high intestinal vs plasma drug exposure, local target engagement, and trends toward reduced UC disease activity. [Clinicaltrials.gov NCT02657122, NCT02818686]
Population Pharmacokinetics and Exposure–Response Relationship of Carfilzomib in Patients With Multiple Myeloma
Ou, Ying , Doshi, Sameer , Nguyen, Anh H. , Jönsson, Fredrik , Aggarwal, Sanjay , Rajangam, Kanya, Dimopoulos, Meletios Α. , Stewart, A. Keith, Badros, Ashraf , Papadopoulos, Kyriakos P. , Vij, Ravi , Niesvizky, Rubén, Graham, Richard, Visich, Jenn, Siegel, David S. , Jagannath, Sundar , Dimopoulos, Meletios A

Mayo Clinic

The Journal of Clinical Pharmacology | December 7, 2016 | Volume: 57 | Issue: 5 | Pages: 663-677

10.1002/jcph.850 | PMID 27925676 Get It

AbstractA population pharmacokinetic (PK) model and exposure–response (E‐R) analysis was developed using data collected from 5 phase 1b/2 and 2 phase 3 studies in subjects with multiple myeloma. Subjects receiving intravenous infusion on 2 consecutive days each week for 3 weeks (days 1, 2, 8, 9, 15, and 16) in each cycle at doses ranging from 15 to 20/56 mg/m2 (20 mg/m2 in cycle 1 and, if tolerated, escalated to 56 mg/m2 on day 8 of cycle 1). The population PK analysis indicated that among all the covariates tested, the only statistically significant covariate was body surface area on carfilzomib clearance; however, this covariate was unlikely to be clinically significant. Despite inclusion of different populations (relapsed or relapsed/refractory), treatments (carfilzomib monotherapy or combination therapy), infusion lengths (2 to 10 minutes or 30 minutes), and different doses, the E‐R analysis of efficacy showed that after adjusting for baseline characteristics, higher area under the concentration–time curve was associated with improved overall response rate (ORR), from 15 to 20/56 mg/m2. No positive relationships between maximum concentration and ORR were identified, indicating that ORR would not be expected to be impacted by infusion length. For safety end points, no statistically significant relationship between exposure and increasing risk of adverse events was identified. The results of an E‐R analysis provided strong support for a carfilzomib dose at 20/56 mg/m2 as a 30‐minute infusion for monotherapy and combination therapy. This article illustrates an example of application of E‐R analysis to support labeling dose recommendation in the absence of extensive clinical data.
PTU-137 Enhanced Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by History and Diagnostic Evaluation
Sood, Ruchit , Camilleri, Michael , Gracie, DJ, Gold, M S, To, N., Ford, Alexander C. , Law, Graham Richard , Ford, Alexander C

Mayo Clinic

BSG 2016 | November 23, 2016 | Volume: No volume available | Issue: No issue available | Pages: A125.1-A125

10.1136/gutjnl-2016-312388.223 Get It